Skip to main content
Premium Trial:

Request an Annual Quote

NimbleGen Raises $12.8 Million in Venture Capital Round

NEW YORK, Nov. 1 (GenomeWeb News) - NimbleGen Systems has raised $12.75 million in a series F round of venture capital financing, the company said today.

 

Current investors Baird Venture Partners and Venture Investors led the round; new investors included Cargill Ventures and Topspin Partners, as well as all of the company's other existing venture capital and institutional investors.

 

The new round brings to $41 million the total amount of private-equity financing NimbleGen has raised since its founding in 2000.

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.